Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study* of more than 50,000 women published in Cancer.
The study, which was funded by the American Cancer Society and used data on women in Sweden, found that women who had chosen to participate in an organised breast cancer screening programme had a 60 per cent lower risk of dying from breast cancer within 10 years after diagnosis, and a 47 per cent lower risk of dying from breast cancer within 20 years after diagnosis.
Evgen Pharma (LON:EVG) is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company’s core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
